Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. - Wikidata - wikimedia - TriplyDB

Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions.

Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions.

http://www.wikidata.org/entity/Q34861181

about

A Photoactive Carbon-Monoxide-Releasing Protein Cage for Dose-Regulated Delivery in Living Cells Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance.Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus Combinatorial peptide libraries: mining for cell-binding peptides.Multivalent viral capsids with internal cargo for fibrin imaging.Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease.Near infrared imaging and photothermal ablation of vascular inflammation using single-walled carbon nanotubes.Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice Tumor-penetrating peptides.(64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque Fiber-optic system for dual-modality imaging of glucose probes 18F-FDG and 6-NBDG in atherosclerotic plaques Random mutagenesis of amelogenin for engineering protein nanoparticles.Tumor penetrating peptides for improved drug delivery.Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor.Scintillating balloon-enabled fiber-optic system for radionuclide imaging of atherosclerotic plaques.Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions.Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.Cargo-shell and cargo-cargo couplings govern the mechanics of artificially loaded virus-derived cages.Targeting and therapeutic peptides in nanomedicine for atherosclerosis.Multimodality PET/MRI agents targeted to activated macrophages.Peptides as targeting elements and tissue penetration devices for nanoparticles.Functionalization of protein-based nanocages for drug delivery applications.Molecular dynamics, thermodynamic, and mutational binding studies for tumor-specific LyP-1 in complex with p32.Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery.Detection and treatment of atherosclerosis using nanoparticles.Polyvalent display of monosaccharides on ferritin protein cage nanoparticles for the recognition and binding of cell-surface lectins.A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells.Transtumoral targeting enabled by a novel neuropilin-binding peptide.Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide.Metal ion assisted interface re-engineering of a ferritin nanocage for enhanced biofunctions and cancer therapy.Acid-Sensitive Sheddable PEGylated, Mannose-Modified Nanoparticles Increase the Delivery of Betamethasone to Chronic Inflammation Sites in a Mouse Model.The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research.A Dual-Modality Hybrid Imaging System Harnesses Radioluminescence and Sound to Reveal Molecular Pathology of Atherosclerotic Plaques.

P2860

Q27702074-A5914BA3-8044-4E13-A7CA-5DEECDC6FAE2 Q30533932-8B916290-E9E2-44C4-AED4-DDF0FEA909BD Q30587267-525A9FB4-C42E-4263-B9E7-76421C3BD0F4 Q31144876-F817D30D-270C-4068-952A-3F44085062A1 Q33800320-DDBFF0B8-30B8-4A0C-8682-8828D29225A3 Q33949943-84380368-2D48-45E8-863E-33BE9BFEE54A Q34547172-1DC23877-175F-4158-825D-84643F36F8CA Q34880268-5AC7F678-B583-40CF-AFFC-5705EDEC6D56 Q34976054-9C698B90-6967-44F0-9549-6BDCEF9E72C1 Q35030851-C3AD5469-5ADC-488F-96F7-107CD67204A7 Q35262149-2C2E0C2D-9C45-45C8-8B0D-370FA14C9C04 Q35558223-AEA383B8-17D6-47E8-8763-635FA7D76DA5 Q35978545-B89C7104-2F55-437D-8028-4356FC66495F Q36136393-37D0CE99-D2EA-42E3-9237-B2EF875BCB62 Q36263643-B6FE38C7-BA1D-41F6-8D1D-778FAD597433 Q36596084-52A3B941-3F85-462D-8C0A-AEE67D46FB37 Q36598388-004775EF-26D8-4169-BC45-4F15558A8B15 Q36687313-9E31843B-DE6E-4839-B4FC-F1F7A4B27631 Q36884237-EBEF3C52-B0DE-4864-8660-A0BFBB052DF3 Q36913594-0A070B70-2F84-41F5-8E78-6698EC369F9A Q37625234-07E8A6FF-B038-4ABE-A102-AD014580D9A6 Q37627407-50638A32-B139-46A4-99EF-895E29F3FF8B Q38214775-3660E8CC-DC3E-4164-8BF7-05F07CD87AE5 Q38828282-2B32D310-F0BA-4306-ADE6-2539F104A93D Q38841362-0F4BDC00-BD3E-455F-BF9F-3F651D01636F Q38848673-DD94D333-46C2-4A97-A888-A4075D50525E Q39025143-1B8B1613-F9B7-4A65-9110-B87A8164106F Q39124984-39E5A7F6-CA50-40A6-AE10-6A92A689E494 Q39426043-20F9F5E1-25A6-4C82-AE7B-CDCE8F920926 Q42356786-728A74E1-BE27-456D-84B4-CCD95E4558C8 Q45299208-4853A13B-2077-4881-ADBC-1D1FD2DCE72C Q46125533-66F7EF4B-2810-40E5-9E3A-D4632943421C Q47225124-E17D88AC-1A07-4602-A860-4DA1B3CBC10A Q48207924-CAFDECE1-BAA5-450B-AA4A-EC3E8C024485 Q54402965-AD80150E-3B56-4EA0-8745-D705FC5269B2 Q55339713-C1BA7F29-534A-46DB-AEFD-361FB6A3DE5E

P2860

Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions.

http://www.wikidata.org/entity/Q34861181

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@ast

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@en

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@nl

type

label

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@ast

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@en

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@nl

prefLabel

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@ast

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@en

Protein cage nanoparticles bea ...... rophage-rich vascular lesions.

@nl

P1433

Q34861181-B9D1E06B-3842-4E68-B3AE-6F3D8E263C47

P1476

Q34861181-2DA8C469-77F3-4F80-A2AF-4765E09C978B

P2093

Q34861181-3E289C33-59B4-47FB-A6B1-7F7DAF686C1F

Q34861181-4E90E11D-9D11-4031-839E-D501C2183D06

Q34861181-66ECACAD-CE35-44BB-B263-B85A26ECC74F

Q34861181-69ED89EA-9E2E-47E1-9D37-1AA32D55F3B5

Q34861181-77C6FAC4-4CB9-44E6-81D7-4359FB5DDA77

Q34861181-889E897E-10BA-41B7-B7F8-0DE3E8C671A7

P2860

Q34861181-03895490-EBC5-4CD0-900F-DC032C7C138D

Q34861181-04F5B1BA-4890-476C-B164-8D619F5C1859

Q34861181-05AB69AC-C6A9-4A47-BA16-4A5A723D47DA

Q34861181-070EF363-A566-47D0-838C-1144046060EB

Q34861181-0989C6A9-9840-4F91-A5AC-5B5586F1C06B

Q34861181-0A6CF1DB-607C-4260-BA50-C4195D5F61C0

Q34861181-0DC107A9-E4F7-49F1-AE89-56A94D77097B

Q34861181-101ABA73-C121-4325-A3B7-6492FFE0BDE5

Q34861181-1C53111B-200D-40AE-B220-33D472528AAD

Q34861181-1F129176-6C21-4BE9-9C1C-2362B1B35F17

P304

Q34861181-A6D54215-0A8C-4035-AFD5-DD7369E20387

P31

Q34861181-F5CD2E38-71AD-489B-BA5C-358913391B02

P356

Q34861181-EA7E4195-F5A0-4680-A73F-73B955970FF7

P407

Q34861181-CE44A626-A47D-4198-A251-1B46FF81FC3A

P433

Q34861181-0CB29C55-F221-4B43-9D34-9EC3A0F7E798

P478

Q34861181-C3EED4CC-F74A-4F28-81AA-37D2C32C9771

P50

Q34861181-BAB99741-020C-4E20-B6A9-98BE9026F20B

Q34861181-F0DAEE8A-F864-4935-809D-67C7FA0DE174

P577

Q34861181-2509133F-D384-4FBB-8FCA-34CA32170C03

P5875

Q34861181-8A3BBA4A-AAE8-45AA-9CF1-57394D87C579

P698

Q34861181-F4895588-83FA-4D30-9A4F-A6E4A8047209

P921

Q34861181-1CA7D3DA-D395-4B95-95A1-05ED18717200

Q34861181-707ED67E-DA8C-49EA-A23A-37EB3CF11A22

P932

Q34861181-F1F919EF-E0BC-4688-A033-F722F7E42360

P356

P1433

P1476

Protein cage nanoparticles bea ...... crophage-rich vascular lesions

@en

P2093

Deborah A Willits

http://www.w3.org/2001/XMLSchema#string

Hisanori Kosuge

http://www.w3.org/2001/XMLSchema#string

Lars O Liepold

http://www.w3.org/2001/XMLSchema#string

Mark J Young

http://www.w3.org/2001/XMLSchema#string

Masahiro Terashima

http://www.w3.org/2001/XMLSchema#string

Trevor Douglas

http://www.w3.org/2001/XMLSchema#string

P2860

Atherosclerosis — An Inflammatory Disease

Crystal structure of a small heat-shock protein

FeCo/graphite nanocrystals for multi-modality imaging of experimental vascular inflammation

Inflammation in atherosclerosis

In-gel digestion for mass spectrometric characterization of proteins and proteomes

Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents.

High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents.

A tumor-homing peptide with a targeting specificity related to lymphatic vessels.

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

Viruses: making friends with old foes.

P304

2493-2502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/NN102863Y

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Michael V McConnell

P577

2011-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50362138

http://www.w3.org/2001/XMLSchema#string

P698

21391720

http://www.w3.org/2001/XMLSchema#string

P921

P932

3082619

http://www.w3.org/2001/XMLSchema#string